Please assess the completion status of the following clinical trial:

Trial Title: Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be age 18 years or older.~* Patients must have a histologically-confirmed diagnosis of low-grade or follicular non-Hodgkin's B-cell lymphoma.~* Patients must have Ann Arbor stage III or IV extent of disease after completing staging.~* Patients must have bi-dimensionally measurable disease. At least one lesion must have both perpendicular diameters \> 2 cm.~* Patients must have evidence that their tumor expresses the CD20 antigen by immunohistochemistry or flow cytometry.~* Patients must have no previous treatment for NHL.~* Patients must have a Karnofsky performance status of at least 60% and an anticipated survival of at least 3 months.~* Patients must have absolute granulocyte count greater than or equal to 1500 cells/mm3 and a platelet count \> 100,000 cells/mm3 within 14 days of study entry and not require sustained support with hematopoietic cytokines or transfusion of blood products.~* Patients must have adequate renal and hepatic function.~* Patients must sign IRB approved informed consent form(s) prior to study entry.~Exclusion Criteria:~* Patients who received systemic steroids within 1 week of study entry, except patients on maintenance steroid therapy for a non-cancerous disease.~* Patients with evidence of active infection requiring intravenous antibiotics at the time of study entry.~* Patients with New York Heart Association class III or IV heart disease or other serious illness that would preclude evaluation.~* Patients with known HIV Infection.~* Patients with known brain or leptomeningeal metastases.~* Patients who are pregnant or nursing. Patients of childbearing potential must undergo a pregnancy test at screening and on the day fludarabine treatment is started. Treatment is not to be administered until a negative result is obtained. Males and females must agree to use effective contraception for 6 months following the iodine I 131 tositumomab therapy.~* Patients with prior malignancy other than lymphoma, except for adequately-treated skin cancer in situ cervical cancer, or other cancer for which the patient has been disease-free for 5 years.~* Patients with hypersensitivity to fludarabine.~* Patients who are receiving either approved or non-approved (through another protocol) anti-cancer drugs or biologics.~* Patients who are HAMA positive.~* Patients with previous allergic reaction to iodine. This does not include reacting to intravenous iodine containing contrast materials.~Inclusion Criteria for Iodine I 131 Tositumomab Therapy~* Patients who completed 3 cycles of fludarabine.~* Patients must have absolute granulocyte count ≥ to 1500/mm3, platelet count of ≥ 100,000/mm3 (≥ 150,000/mm3 if \> 25% bone marrow involvement at restaging), and not require sustained support with hematopoietic cytokines or transfusions with blood products.~* Patients must have adequate renal and hepatic function.~Exclusion criteria for Antibody Therapy~* Patients with active obstructive hydronephrosis.~* Patients with evidence of active infection requiring intravenous antibiotics.~* Patients who are pregnant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Patients will first receive an abbreviated course of three cycles of fludarabine (25 mg/m2 for 5 days every 5 weeks). Iodine I 131 tositumomab will be initiated 6 to 8 weeks after completion of fludarabine. Patients will undergo dosimetry studies to determine the appropriate patient-specific activity of iodine I 131 tositumomab required to deliver a fixed dose of 75 cGy. The dose will be attenuated to 65 cGy for patients with platelet counts between 100,000 and 150,000/micoliter.

Based on this trial design, predict the completion outcome and termination type (if applicable).